down arrow

Elicio Therapeutics, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US28657F1030
USD
8.32
0.78 (10.41%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

7.838.59

52 Week

4.6012.62
Valuation
Technical
Day's Volume

CASH

86.63 k

Shareholding (Mar 2025)

FII

0.19%

Held by 5 FIIs

DII

96.13%

Held by 4 DIIs

Promoter

0.00%

How big is Elicio Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Elicio Therapeutics, Inc. has a market capitalization of 127.29 million, with recent net sales of 0.00 million and a net profit of -51.28 million for the last four quarters. As of December 2024, the company reported shareholder's funds of -11.31 million and total assets of 28.18 million.

Market Cap: As of Jun 18, Elicio Therapeutics, Inc. has a market capitalization of 127.29 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters ending in March 2025, December 2024, September 2024, and June 2024, Elicio Therapeutics, Inc. reported net sales of 0.00 million and a net profit of -51.28 million.<BR><BR>Balance Sheet Snapshot: As of December 2024, the company reported shareholder's funds of -11.31 million and total assets of 28.18 million.

Read More

What does Elicio Therapeutics, Inc. do?

22-Jun-2025

Elicio Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $11 million and a market cap of $127.29 million. Key financial metrics include a P/E ratio of NA, a dividend yield of 0.00%, and a return on equity of -508.10%.

Overview: <BR>Elicio Therapeutics, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Net Profit: -11 Million (Quarterly Results - Mar 2025) <BR>Market Cap: USD 127.29 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -2.03 <BR>Return on Equity: -508.10% <BR>Price to Book: 14.30<BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Read More

Is Elicio Therapeutics, Inc. overvalued or undervalued?

25-Jun-2025

As of May 10, 2023, Elicio Therapeutics, Inc. is considered overvalued with a valuation grade of "does not qualify" due to negative financial metrics, including a Price to Book Value of 14.08 and an alarming Return on Equity of -508.10%, despite a year-to-date stock performance of 57.25%.

As of 10 May 2023, Elicio Therapeutics, Inc. has moved from a valuation grade of risky to does not qualify, indicating a significant deterioration in its financial standing. The company is currently considered overvalued, given its negative financial metrics, including a Price to Book Value of 14.08 and an EV to EBIT of -2.36. Additionally, the Return on Equity (ROE) is alarmingly low at -508.10%, reflecting severe inefficiencies in generating profit from equity.<BR><BR>In comparison to its peers, Elicio's metrics are concerning. For instance, Avrobio, Inc. has an EV to EBITDA of -1.2033, while Eliem Therapeutics, Inc. shows a more favorable EV to EBITDA of 0.3575. These comparisons highlight Elicio's relative weakness in the market. Despite a recent strong performance against the S&P 500, with a year-to-date return of 57.25% compared to 2.44% for the index, the underlying financial ratios suggest that the stock is not justified at its current price level of 8.02.

Read More

Is Elicio Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of June 17, 2025, Elicio Therapeutics, Inc. shows a bullish technical trend with strong momentum indicators, including a 124.8% year-to-date return compared to the S&P 500's 12.22%.

As of 17 June 2025, the technical trend for Elicio Therapeutics, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, and the daily moving averages also indicate a bullish stance. The Bollinger Bands show a bullish signal on the monthly timeframe, while the KST is bullish on both weekly and monthly periods. The stock has demonstrated strong performance year-to-date with a return of 124.8%, significantly outperforming the S&P 500's 12.22% return. Overall, the current technical stance is bullish with strong momentum indicators supporting this view.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 191 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-6.43

stock-summary
Return on Equity

-2,404.47%

stock-summary
Price to Book

104.32

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-11 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-19.64%
0%
-19.64%
6 Months
3.03%
0%
3.03%
1 Year
66.5%
0%
66.5%
2 Years
41.34%
0%
41.34%
3 Years
804.89%
0%
804.89%
4 Years
-75.07%
0%
-75.07%
5 Years
0%
0%
0.0%

Elicio Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Elicio Therapeutics, Inc. technically bullish or bearish?

As of 17 June 2025, the technical trend for Elicio Therapeutics, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, and the daily moving averages also indicate a bullish stance. The Bollinger Bands show a bullish signal on the monthly timeframe, while the KST is bullish on both weekly and monthly periods. The stock has demonstrated strong performance year-to-date with a return of 124.8%, significantly outperforming the S&P 500's 12.22% return. Overall, the current technical stance is bullish with strong momentum indicators supporting this view....

Read More
Elicio Therapeutics Hits New 52-Week High of $12.61

Elicio Therapeutics Hits New 52-Week High of $12.61

Elicio Therapeutics, Inc. achieved a new 52-week high, reflecting strong performance over the past year, significantly outpacing the S&P 500. With a market capitalization of USD 191 million, the company, despite being unprofitable, shows potential in the Pharmaceuticals & Biotechnology sector, emphasizing growth over immediate returns.

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-100.00%
EBIT Growth (5y)
6.74%
EBIT to Interest (avg)
-27.45
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-2.03
Sales to Capital Employed (avg)
0.04
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
15.24%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
14.08
EV to EBIT
-2.36
EV to EBITDA
-2.42
EV to Capital Employed
-11.65
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-508.10%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 5 Schemes (3.68%)

Foreign Institutions

Held by 5 Foreign Institutions (0.19%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 5.36% vs 20.00% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-9.80",
          "val2": "-10.50",
          "chgp": "6.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.20",
          "val2": "0.20",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.90",
          "val2": "-0.50",
          "chgp": "-80.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-10.60",
          "val2": "-11.20",
          "chgp": "5.36%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -47.44% vs -24.82% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-43.80",
          "val2": "-34.60",
          "chgp": "-26.59%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.50",
          "val2": "1.10",
          "chgp": "-54.55%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-7.40",
          "val2": "1.00",
          "chgp": "-840.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-51.90",
          "val2": "-35.20",
          "chgp": "-47.44%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-9.80
-10.50
6.67%
Interest
0.20
0.20
Exceptional Items
-0.90
-0.50
-80.00%
Consolidate Net Profit
-10.60
-11.20
5.36%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 5.36% vs 20.00% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-43.80
-34.60
-26.59%
Interest
0.50
1.10
-54.55%
Exceptional Items
-7.40
1.00
-840.00%
Consolidate Net Profit
-51.90
-35.20
-47.44%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -47.44% vs -24.82% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Elicio Therapeutics, Inc. stock-summary
stock-summary
Elicio Therapeutics, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."